Interplay between the ubiquitin-proteasome system and autophagy in proteinopathies

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 1, Issue 2, 2009, Pages 127-142

  Zheng, Qingwen ^a   Li, Jie ^a   Wang, Xuejun ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Lee Medical Building ^*  (United States)

Author keywords

Autophagy; FoxO3; HADC6; p62; Proteinopathy; Ubiquitin proteasome system

Indexed keywords

HISTONE DEACETYLASE 6; PROTEASOME; UBIQUITIN;

AUTOPHAGY; CARDIOMYOPATHY; CELL ORGANELLE; CYTOPLASM; DEGENERATIVE DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; LIFESTYLE MODIFICATION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN QUALITY; QUALITY CONTROL; REVIEW; STARVATION;

EID: 77953436021     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Taylor JP, Hardy J and Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002; 296: 1991-1995.
2. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, Xie SX, Kwong LK, Elman L, McCluskey L, Clark CM, Malunda J, Miller BL, Zimmerman EA, Qian J, Van Deerlin V, Grossman M, Lee VM and Trojanowski JQ. Clinical and pathological continuum of multi-system TDP-43 proteinopathies. Arch Neurol 2009; 66: 180-189.
3. Selcen D. Myofibrillar myopathies. Curr Opin Neurol 2008; 21: 585-589.
4. Ferrer I and Olive M. Molecular pathology of myofibrillar myopathies. Expert Rev Mol Med 2008; 10: e25.
5. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klovekorn WP and Schaper J. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003; 92: 715-724.
6. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, Klovekorn WP, Schlepper M, Schaper W and Schaper J. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 2000; 86: 846-853.
7. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A and Robbins J. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 2004; 101: 10132-10136.
8. Tannous P, Zhu H, Nemchenko A, Berry JM, Johnstone JL, Shelton JM, Miller FJ, Jr., Rothermel BA and Hill JA. Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation 2008; 117: 3070-3078.
9. Johnston JA, Ward CL and Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883-1898.
10. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S and Fischbeck KH. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 2003; 12: 749-757.
11. Johnston JA, Illing ME and Kopito RR. Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 2002; 53: 26-38.
12. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10: 524-530.
13. Wang X, Su H and Ranek MJ. Protein quality control and degradation in cardiomyocytes. J Mol Cell Cardiol 2008; 45: 11-27.
14. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995; 7: 215-223.
15. Gomes AV, Zong C and Ping P. Protein degradation by the 26S proteasome system in the normal and stressed myocardium. Antioxid Redox Signal 2006; 8: 1677-1691.
16. Yoshimori T. Autophagy: a regulated bulk degradation process inside cells. Biochem Biophys Res Commun 2004; 313: 453-458.
17. Fuertes G, Villarroya A and Knecht E. Role of proteasomes in the degradation of short-lived proteins in human fibroblasts under various growth conditions. Int J Biochem Cell Biol 2003; 35: 651-664.
18. Fuertes G, Martin De Llano JJ, Villarroya A, Rivett AJ and Knecht E. Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem J 2003; 375: 75-86.
19. Webb JL, Ravikumar B, Atkins J, Skepper JN and Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003; 278: 25009-25013.
20. Ravikumar B, Duden R and Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002; 11: 1107-1117.
21. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ and Rubinsztein DC. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36: 585-595.
22. Kabuta T, Suzuki Y and Wada K. Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome. J Biol Chem 2006; 281: 30524-30533.
23. Martin-Aparicio E, Yamamoto A, Hernandez F, Hen R, Avila J and Lucas JJ. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 2001; 21: 8772-8781.
24. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN and Mouradian MM. Degradation of alpha-synuclein by proteasome. J Biol Chem 1999; 274: 33855-33858.
25. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A, Orr HT, Beaudet AL and Zoghbi HY. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999; 24: 879-892.
26. Verhoef LG, Lindsten K, Masucci MG and Dantuma NP. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 2002; 11: 2689-2700.
27. Kruse KB, Brodsky JL and McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for so luble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. Mol Biol Cell 2006; 17: 203-212.
28. Liu J, Tang M, Mestril R and Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J Mol Cell Cardiol 2006; 40: 451-454.
29. Stefanis L, Larsen KE, Rideout HJ, Sulzer D and Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21: 9549-9560.
30. Shibata M, Lu T, Furuya T, Degterev A, Mizushima N, Yoshimori T, MacDonald M, Yankner B and Yuan J. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J Biol Chem 2006; 281: 14474-14485.
31. Bence NF, Sampat RM and Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292: 1552-1555.
32. Wang X and Robbins J. Heart failure and protein quality control. Circ Res 2006; 99: 1315-1328.
33. Olanow CW and McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. Mov Disord 2006; 21: 1806-1823.
34. Seo H, Sonntag KC and Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004; 56: 319-328.
35. Santos SD, Cardoso I, Magalhaes J and Saraiva MJ. Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. J Pathol 2007; 213: 200-209.
36. McNaught KS, Belizaire R, Isacson O, Jenner P and Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003; 179: 38-46.
37. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, Clarke AR, van Leeuwen FW, Menendez-Benito V, Dantuma NP, Portis JL, Collinge J and Tabrizi SJ. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 2007; 26: 175-188.
38. Mao I, Liu J, Li X and Luo H. REGgamma, a proteasome activator and beyond? Cell Mol Life Sci 2008; 65: 3971-3980.
39. Seo H, Sonntag KC, Kim W, Cattaneo E and Isacson O. Proteasome activator enhances survival of huntington's disease neuronal model cells. PLoS ONE 2007; 2: e238.
40. Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M and Bates GP. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum Mol Genet 2006; 15: 33-44.
41. Diaz-Hernandez M, Hernandez F, Martin-Aparicio E, Gomez-Ramos P, Moran MA, Castano JG, Ferrer I, Avila J and Lucas JJ. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci 2003; 23: 11653-11661.
42. Ding Q, Lewis JJ, Strum KM, Dimayuga E, Bruce-Keller AJ, Dunn JC and Keller JN. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J Biol Chem 2002; 277: 13935-13942.
43. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H and Wanker EE. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001; 12: 1393-1407.
44. Weekes J, Morrison K, Mullen A, Wait R, Barton P and Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003; 3: 208-216.
45. Wang X, Osinska H, Dorn GW, 2nd, Nieman M, Lorenz JN, Gerdes AM, Witt S, Kimball T, Gulick J and Robbins J. Mouse model of desmin-related cardiomyopathy. Circulation 2001; 103: 2402-2407.
46. Wang X, Osinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J, Hewett T and Robbins J. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001; 89: 84-91.
47. Gamez J, Armstrong J, Shatunov A, Selva-O'Callaghan A, Dominguez-Oronoz R, Ortega A, Goldfarb L, Ferrer I and Olive M. Generalized muscle pseudo-hypertrophy and stiffness associated with the myotilin Ser55Phe mutation: a novel myotilinopathy phenotype? J Neurol Sci 2009; 277: 167-171.
48. Chen Q, Liu JB, Horak KM, Zheng H, Kumarapeli AR, Li J, Li F, Gerdes AM, Wawrousek EF and Wang X. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 2005; 97: 1018-1026.
49. Liu J, Chen Q, Huang W, Horak KM, Zheng H, Mestril R and Wang X. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. Faseb J 2006; 20: 362-364.
50. Martindale JJ, Fernandez R, Thuerauf D, Whittaker R, Gude N, Sussman MA and Glembotski CC. Endoplasmic reticulum stress gene induction and protection from ischemia/reperfusion injury in the hearts of transgenic mice with a tamoxifen-regulated form of ATF6. Circ Res 2006; 98: 1186-1193.
51. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B and Szweda LI. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 2001; 276: 30057-30063.
52. Ishii T, Sakurai T, Usami H and Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry 2005; 44: 13893-13901.
53. Farout L, Mary J, Vinh J, Szweda LI and Friguet B. Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependant on 20S proteasome subtypes. Arch Biochem Biophys 2006; 453: 135-142.
54. Divald A and Powell SR. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med 2006; 40: 156-164.
55. Fielitz J, van Rooij E, Spencer JA, Shelton JM, Latif S, van der Nagel R, Bezprozvannaya S, de Windt L, Richardson JA, Bassel-Duby R and Olson EN. Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proc Natl Acad Sci U S A 2007; 104: 4377-4382.
56. Zhang C, Xu Z, He XR, Michael LH and Patterson C. CHIP, a cochaperone/ubiquitin ligase that regulates protein quality control, is required for maximal cardioprotection after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2005; 288: H2836-2842.
57. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H, Liao Y, Okazaki H, Asai M, Hirata A, Fujita M, Asano Y, Yamazaki S, Asanuma H, Hori M and Kitakaze M. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 2006; 340: 1125-1133.
58. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF and Madura K. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 2006; 114: 1821-1828.
59. Balasubramanian S, Mani S, Shiraishi H, Johnston RK, Yamane K, Willey CD, Cooper Gt, Tuxworth WJ and Kuppuswamy D. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J Mol Cell Cardiol 2006; 41: 669-679.
60. Hacihanefioglu A, Tarkun P and Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 2008; 88: 219-222.
61. Voortman J and Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006; 6: 129.
62. McNaught KS, Perl DP, Brownell AL and Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004; 56: 149-162.
63. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443: 780-786.
64. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J and Mayer RJ. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008; 28: 8189-8198.
65. Bedford L, Paine S, Rezvani N, Mee M, Lowe J and Mayer RJ. The UPS and autophagy in chronic neurodegenerative disease: six of one and half a dozen of the other - or not? Autophagy 2009; 5: 224-227.
66. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T and Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 2004; 432: 1032-1036.
67. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E and Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441: 880-884.
68. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H and Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441: 885-889.
69. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B and Wyss-Coray T. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 2008; 118: 2190-2199.
70. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, Nishida K, Hori M, Mizushima N and Otsu K. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007; 13: 619-624.
71. Shacka JJ, Klocke BJ, Young C, Shibata M, Olney JW, Uchiyama Y, Saftig P and Roth KA. Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. J Neurosci 2007; 27: 2081-2090.
72. Myllykangas L, Tyynela J, Page-McCaw A, Rubin GM, Haltia MJ and Feany MB. Cathepsin D-deficient Drosophila recapitulate the key features of neuronal ceroid lipofuscinoses. Neurobiol Dis 2005; 19: 194-199.
73. Tanaka Y, Guhde G, Suter A, Eskelinen EL, Hartmann D, Lullmann-Rauch R, Janssen PM, Blanz J, von Figura K and Saftig P. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000; 406: 902-906.
74. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, Mora M, Riggs JE, Oh SJ, Koga Y, Sue CM, Yamamoto A, Murakami N, Shanske S, Byrne E, Bonilla E, Nonaka I, DiMauro S and Hirano M. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406: 906-910.
75. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI and Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38: 1184-1191.
76. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, MacDonald ME and Cotman SL. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J Biol Chem 2006; 281: 20483-20493.
77. Nedelsky NB, Todd PK and Taylor JP. Autophagy and the ubiquitin-proteasome system: Collaborators in neuroprotection. Biochim Biophys Acta 2008; 1782: 691-699.
78. Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S, Lalli G, Witherden AS, Hummerich H, Nicholson S, Morgan PJ, Oozageer R, Priestley JV, Averill S, King VR, Ball S, Peters J, Toda T, Yamamoto A, Hiraoka Y, Augustin M, Korthaus D, Wattler S, Wabnitz P, Dickneite C, Lampel S, Boehme F, Peraus G, Popp A, Rudelius M, Schlegel J, Fuchs H, Hrabe de Angelis M, Schiavo G, Shima DT, Russ AP, Stumm G, Martin JE and Fisher EM. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003; 300: 808-812.
79. Levy JR, Sumner CJ, Caviston JP, Tokito MK, Ranganathan S, Ligon LA, Wallace KE, LaMonte BH, Harmison GG, Puls I, Fischbeck KH and Holzbaur EL. A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J Cell Biol 2006; 172: 733-745.
80. LaMonte BH, Wallace KE, Holloway BA, Shelly SS, Ascano J, Tokito M, Van Winkle T, Howland DS and Holzbaur EL. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002; 34: 715-727.
81. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B and Rubinsztein DC. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 2006; 76: 89-101.
82. Levine B and Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
83. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A and Cuervo AM. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 2005; 64: 113-122.
84. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC and Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12: 25-31.
85. Kegel KB, Kim M, Sapp E, McIntyre C, Castano JG, Aronin N and DiFiglia M. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 2000; 20: 7268-7278.
86. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H and Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171: 603-614.
87. Nixon RA, Cataldo AM and Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem Res 2000; 25: 1161-1172.
88. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH and Taylor JP. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859-863.
89. Ravikumar B, Acevedo-Arozena A, Imarisio S, Berger Z, Vacher C, O'Kane CJ, Brown SD and Rubinsztein DC. Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat Genet 2005; 37: 771-776.
90. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ and Rubinsztein DC. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006; 15: 433-442.
91. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ and Rubinsztein DC. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 2008; 17: 170-178.
92. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M and Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10: 148-154.
93. Shimomura H, Terasaki F, Hayashi T, Kitaura Y, Isomura T and Suma H. Autophagic degeneration as a possible mechanism of myocardial cell death in dilated cardiomyopathy. Jpn Circ J 2001; 65: 965-968.
94. Tannous P, Zhu H, Johnstone JL, Shelton JM, Rajasekaran NS, Benjamin IJ, Nguyen L, Gerard RD, Levine B, Rothermel BA and Hill JA. Autophagy is an adaptive response in desminrelated cardiomyopathy. Proc Natl Acad Sci U S A 2008; 105: 9745-9750.
95. Ding WX and Yin XM. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 2008; 4: 141-150.
96. Yan L, Vatner DE, Kim SJ, Ge H, Masurekar M, Massover WH, Yang G, Matsui Y, Sadoshima J and Vatner SF. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci U S A 2005; 102: 13807-13812.
97. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B and Sadoshima J. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007; 100: 914-922.
98. Hamacher-Brady A, Brady NR and Gottlieb RA. Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem 2006; 281: 29776-29787.
99. Valentim L, Laurence KM, Townsend PA, Carroll CJ, Soond S, Scarabelli TM, Knight RA, Latchman DS and Stephanou A. Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol 2006; 40: 846-852.
100. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA, Le V, Levine B, Rothermel BA and Hill JA. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007; 117: 1782-1793.
101. Rothermel BA and Hill JA. Autophagy in load-induced heart disease. Circ Res 2008; 103: 1363-1369.
102. Pan T, Kondo S, Zhu W, Xie W, Jankovic J and Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 2008; 32: 16-25.
103. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D and Yin XM. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007; 171: 513-524.
104. Hebert DN and Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev 2007; 87: 1377-1408.
105. Schroder M and Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-789.
106. Harding HP, Calfon M, Urano F, Novoa I and Ron D. Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol 2002; 18: 575-599.
107. Glembotski CC. Endoplasmic reticulum stress in the heart. Circ Res 2007; 101: 975-984.
108. Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, Hayashi YK and Momoi T. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet 2007; 16: 618-629.
109. Kouroku Y, Fujita E, Tanida I, Ueno T, Isoai A, Kumagai H, Ogawa S, Kaufman RJ, Kominami E and Momoi T. ER stress (PERK/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ 2007; 14: 230-239.
110. Ding WX, Ni HM, Gao W, Hou YF, Melan MA, Chen X, Stolz DB, Shao ZM and Yin XM. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem 2007; 282: 4702-4710.
111. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, Murakami T, Taniguchi M, Tanii I, Yoshinaga K, Shiosaka S, Hammarback JA, Urano F and Imaizumi K. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 2006; 26: 9220-9231.
112. Rao RV, Ellerby HM and Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004; 11: 372-380.
113. Harada M, Hanada S, Toivola DM, Ghori N and Omary MB. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. Hepatology 2008; 47: 2026-2035.
114. Pankiv S, Hoyvarde Clausen T, Lamark T, Brech A, Bruun JA, Outzen H, Overvatn A, Bjorkoy G and Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of Ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 19: 19.
115. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR and Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 24: 8055-8068.
116. Bjorkoy G, Lamark T and Johansen T. p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2006; 2: 138-139.
117. Nagaoka U, Kim K, Jana NR, Doi H, Maruyama M, Mitsui K, Oyama F and Nukina N. Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem 2004; 91: 57-68.
118. Kuusisto E, Salminen A and Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002; 28: 228-237.
119. Kuusisto E, Salminen A and Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001; 12: 2085-2090.
120. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A and Denk H. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 2002; 160: 255-263.
121. Ishii T, Yanagawa T, Yuki K, Kawane T, Yoshida H and Bannai S. Low micromolar levels of hydrogen peroxide and proteasome inhibitors in duce the 60-kDa A170 stress protein in murine peritoneal macrophages. Biochem Biophys Res Commun 1997; 232: 33-37.
122. Yue Z. Regulation of neuronal autophagy in axon: implication of autophagy in axonal function and dysfunction/degeneration. Autophagy 2007; 3: 139-141.
123. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-175.
124. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata JI, Ezaki J, Murata S, Hamazaki J, Nishito Y, Iemura SI, Natsume T, Yanagawa T, Uwayama J, Warabi E, Yoshida H, Ishii T, Kobayashi A, Yamamoto M, Yue Z, Uchiyama Y, Kominami E and Tanaka K. Homeostatic Levels of p62 Control Cytoplasmic Inclusion Body Formation in Autophagy-Deficient Mice. Cell 2007; 131: 1149-1163.
125. Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kemppainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT, Moscat J and Wooten MW. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 2008; 106: 107-120.
126. Iwata A, Riley BE, Johnston JA and Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005; 280: 40282-40292.
127. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A and Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738.
128. Tan JM, Wong ES, Dawson VL, Dawson TM and Lim KL. Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. Autophagy 2007; 4: 2.
129. Olzmann JA, Li L, Chudaev MV, Chen J, Perez FA, Palmiter RD and Chin LS. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 2007; 178: 1025-1038.
130. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH and Goldberg AL. Fox-O3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6: 472-483.
131. Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL and Walsh K. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005; 280: 20814-20823.
132. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S and Sandri M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458-471.
133. Ravikumar B, Berger Z, Vacher C, O'Kane CJ and Rubinsztein DC. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006; 15: 1209-1216.